Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine

Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine

Introduction The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in significant morbidity and mortality worldwide. As SARS-CoV-2 moves into endemic status, vaccination remains a key element in protecting the health of...

Full description

Bibliographic Details
Main Authors: Eddie Underwood, Lisa M. Dunkle, Shabir A. Madhi, Cynthia L. Gay, Paul T. Heath, Karen L. Kotloff, Katherine Smith, Gordon Chau, Shirley Galbiati, Alice McGarry, Wayne Woo, Iksung Cho, Katia Alves, Germán Áñez, Chijioke Bennett, Vivek Shinde, Louis Fries, Raburn M. Mallory, Gregory M. Glenn, Seth Toback
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Expert Review of Vaccines
Subjects:
clinical trial
coronavirus
covid-19, matrix-m adjuvant
prevention
protein-based vaccine
sars-cov-2
vaccination
nvx-cov2373
Online Access:http://dx.doi.org/10.1080/14760584.2023.2218913

Internet

http://dx.doi.org/10.1080/14760584.2023.2218913

Similar Items